Skip to main content Help with accessibility Skip to main navigation

Shared-care Guidelines

 Click here for a downloadable word document of the shared care agreement forms: 

DMARDs Shared Care Agreement (Version 1.1) 

Generic Shared Care Agreement Form 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2018
BNF chapter: Central nervous system

Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine - For Attention Deficit Hyperactivity Disorder in adults aged over 17 years and in children and adolescents aged 6 to 17 years

Guanfacine - For Attention Deficit Hyperactivity Disorder in children and adolescents aged 6 to 17 years 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2014
BNF chapter: Central nervous system

Amisulpride, Aripiprazole, Olanzapine, Quetiapine, Oral Risperidone
This shared prescribing guideline for the second-generation antipsychotic medications listed above has been developed with due consideration to the appropriate NICE Clinical Guidelines (CG) e.g. Bipolar Disorder (CG185), Psychosis and Schizophrenia in Children and Young People (CG155), Psychosis and Schizophrenia in Adults (CG178), Schizophrenia- Aripiprazole (TA213), Bipolar Disorder- Adolescents (TA292).

Please note: Morecambe Bay CCG has now adopted this Shared-care guideline for all areas, including South Cumbria. 

 

Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2017
BNF chapter: Central nervous system

Refer to Local Commissioning Policy Before Use

Treatment of Parkinson’s Disease

 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - May - 2014
BNF chapter: Central nervous system

Licensed Indications

  1. In the management of acute mania or hypomanic episodes
  2. In the management of episodes of recurrent depressive disorders where treatment with other antidepressants has been unsuccessful
  3. In the prophylaxis against bipolar affective disorders
  4. Control of aggressive behaviours of intentional self-harm.
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2015

To extend life or the time to mechanical ventilation for adult patients with amyotrophic lateral sclerosis (ALS) 1,2, variant of Motor Neurone Disease (MND). Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not be used in patients with any other forms of MND. Riluzole should only be initiated by a neurological specialist with expertise in the management of MND (as per NICE TA 20, 2001)

It is expected that most patients will be managed by secondary care however this guideline is those patients who need to be managed in community